Answers are grounded in this paper and cite their sources.
Cancer vaccines aim to enhance antitumor immune responses by targeting antigen-presenting cells (APCs) to promote T-lymphocyte recruitment and infiltration, thereby suppressing tumor progression. However, in the absence of sufficient antigenic stimulation, precise targeting and activation of dendritic cells (DCs) remain challenging, substantially limiting the efficacy of antigen-based immunotherapies. Here, we report an adhesive catalytic nanoreservoir (CN) composed of manganese dioxide (MnO 2 ) and a catechol-functionalized magnetic metal–organic framework for in situ antigen capture and dual-organ delivery to reprogram T-cell immunity. Following intravenous administration, CN accumulates at lung metastasis tumors via margination-mediated targeting and undergoes in situ gelation, enabling efficient capture of tumor antigens. At tumor, CN releases Mn 2 ⁺ ions, triggering redox reactions through glutathione (GSH) depletion and Fenton-like activity to induce chemodynamic therapy (CDT). This CDT process promotes the release of tumor-associated antigens (TAAs), while the catechol-rich gel matrix as a local antigen reservoir, sustaining immune stimulation. Concurrently, CN exhibits spleen-targeting, allowing preloaded TAAs to traverse the lymphoreticular network and facilitate DC sampling, thereby activating naïve T cells and amplifying systemic antitumor immunity. The in situ–formed catalytic nanoreservoir in lung metastases and the spleen, acting as CDT-induced antigen depots, suppressed tumor progression for over 60 days and prolonged survival.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: